Literature DB >> 12376076

Insulin resistance: a metabolic link between depressive disorder and atherosclerotic vascular diseases.

R Ramasubbu1.   

Abstract

The association of depression with insulin resistance (IR) and athersclerotic vascular diseases has been well documented. This review examines the relevance of IR as a link between depressive disorder and atherosclerotic vascular diseases. Relevant articles collected from Medline database over the period of 1966-2001 were reviewed. Studies have shown that IR is a state-dependent abnormality in depression and depression increases the risk of vascular morbidity and mortality. Given that IR is a central component of cardiovascular risk factors, depression-related IR might play a role in the development and progression of coronary and cerebral atherosclerosis in chronic-resistant depression. Further, IR may contribute to the pathophysiology of depressive disorder. In conclusion IR could account for the linkage between depression and atherosclerotic vascular diseases. More studies are needed to examine the importance of improving insulin sensitivity in the treatment of chronic-resistant depression and prevention of depression-related vascular morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376076     DOI: 10.1016/s0306-9877(02)00244-x

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  21 in total

Review 1.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

Review 2.  Pathophysiological basis of cardiovascular disease and depression: a chicken-and-egg dilemma.

Authors:  Gilberto Paz-Filho; Julio Licinio; Ma-Li Wong
Journal:  Braz J Psychiatry       Date:  2010-06       Impact factor: 2.697

3.  Is early- and late-onset depression after acute myocardial infarction associated with long-term survival in older adults? A population-based study.

Authors:  Gilat L Grunau; Pamela A Ratner; Elliot M Goldner; Sam Sheps
Journal:  Can J Cardiol       Date:  2006-05-01       Impact factor: 5.223

4.  Brain and behavioral correlates of insulin resistance in youth with depression and obesity.

Authors:  Manpreet K Singh; Sara M Leslie; Mary Melissa Packer; Yevgeniya V Zaiko; Owen R Phillips; Elizabeth F Weisman; Danielle M Wall; Booil Jo; Natalie Rasgon
Journal:  Horm Behav       Date:  2018-04-23       Impact factor: 3.587

5.  Obstructive sleep apnea and depression: a review.

Authors:  Shakir M Ejaz; Imran S Khawaja; Subhash Bhatia; Thomas D Hurwitz
Journal:  Innov Clin Neurosci       Date:  2011-08

6.  Metabolic Effects of Antidepressant Treatment.

Authors:  Özlem Olguner Eker; Saliha Özsoy; Baki Eker; Hatice Doğan
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

Review 7.  Behavioral genetics of the depression/cancer correlation: a look at the Ras oncogene family and the 'cerebral diabetes paradigm'.

Authors:  Janet K Brewer
Journal:  J Mol Neurosci       Date:  2008-06-18       Impact factor: 3.444

8.  Depression and insulin resistance: cross-sectional associations in young adults.

Authors:  Sue Pearson; Mike Schmidt; George Patton; Terry Dwyer; Leigh Blizzard; Petr Otahal; Alison Venn
Journal:  Diabetes Care       Date:  2010-02-25       Impact factor: 19.112

9.  Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases.

Authors:  Charles D Nichols
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-10-13

10.  Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis.

Authors:  M J Knol; J W R Twisk; A T F Beekman; R J Heine; F J Snoek; F Pouwer
Journal:  Diabetologia       Date:  2006-03-07       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.